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Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based 
therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected 
number of unexplained deaths were reported with front-line ibrutinib in a patient population 
aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.
Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib 
was associated with a greater mortality in older patients outside of a clinical trial setting. This 
multicenter analysis was performed by investigators at 20 academic and community 
practices.
Results: Amongst the 391 patients included, there was no correlation between age and 
response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65- 
years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).
Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in 
an older population. Patients should be educated regarding the potential complications 
related to ibrutinib and symptoms of concern to report.
Keywords: CLL, ibrutinib, elderly
Introduction
Recently published cooperative group studies, Alliance A041202 and ECOG E1912, 
have established the role of ibrutinib over chemoimmunotherapy for the front-line 
treatment of chronic lymphocytic leukemia (CLL).1,2 Notably, Alliance A041202, 
which evaluated patients ≥65-years-old receiving ibrutinib with or without rituximab 
or the combination of bendamustine and rituximab (BR), reported a higher than 
expected number of deaths in both of the ibrutinib-containing arms.1 Ten unex-
plained/unknown deaths occurred among the 361 patients receiving ibrutinib; whereas 
1 such event occurred in the BR arm (n=176). These data were in contrast to ECOG 
E1912 in which ibrutinib plus rituximab was associated with an improvement in 
overall survival (OS) compared to FCR (fludarabine, cyclophosphamide, rituximab) 
in patients less than 70 years of age.2 Together, these data suggest ibrutinib may be 
associated with significant adverse events (AE) and greater mortality in an elderly 
CLL population. We sought to investigate this hypothesis in previously untreated 
patients who received commercially available ibrutinib as initial therapy for CLL.
Methods
This multicenter retrospective analysis was performed by investigators at 20 academic 
and community practices. The study was approved by the institutional review board at 
Correspondence: Chaitra Ujjani  
Seattle Cancer Care Alliance, Fred Hutchinson 
Cancer Research Center, 825 Eastlake Ave E, 
Mail Stop CE3-300, Seattle, WA, USA  
Tel +1 206-606-1955  
Fax +1 206-606-1130  
Email ujjani@uw.edu
Blood and Lymphatic Cancer: Targets and Therapy                               Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Blood and Lymphatic Cancer: Targets and Therapy 2020:10 1–5                                               1
http://doi.org/10.2147/BLCTT.S262592 
DovePress © 2020 Ujjani et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
each participating institution (Supplementary Materials). 
Informed consent was waived because the research involved 
no more than minimal risk to the patient. In compliance with 
the Declaration of Helsinki, patient confidentiality was main-
tained through de-identified data collection practices. 
Patients were considered eligible for inclusion if they 
received ibrutinib for the front-line treatment of CLL through 
commercial sources. Medical chart review via diagnostic 
codes was performed to identify all CLL patients at each 
institution. Investigators utilized chart review, electronic 
medical records, and related databases to obtain required 
information. Patient demographics, prognostic markers, ibru-
tinib dosing administration, and clinical outcomes data were 
collected. The International Workshop on Chronic 
Lymphocytic Leukemia (iwCLL, 2008) criteria were used 
to define response and progression of disease.3
The primary endpoint was OS as determined by the 
Kaplan Meier method.4 OS was defined as time from initia-
tion of ibrutinib to death. Comparisons of survival were 
made using COX regression analyses.5,6 All other compar-
ison analyses were descriptive. Early deaths were defined as 
a death from any cause occurring within 12 months of 
ibrutinib treatment initiation. Secondary endpoints included 
response rates, progression-free survival (PFS), discontinua-
tion rates, and reasons for discontinuation. PFS was defined 
as time from ibrutinib initiation to progression or death from 
any cause. Patients were otherwise censored at the time of 
last follow-up. Statistical analyses were performed using 
STATA 10.1 (Stata Statistical Software: Release 10, 2007; 
StataCorp LP, College Station, TX). All tests were two-sided 
at the 5% level.
Results
Of the 391 patients identified, 59% were 65 years or older 
(≥65 YO). The median age at initiation of ibrutinib was 63 
years (range 36–96). Patient characteristics are detailed in 
Table 1. Poor risk prognostic features were similar in 
patients stratified by age at start of ibrutinib (≥65 YO 
and <65 YO cohorts, respectively): del 17p (29%, 30%), 
TP53 mutation (21%, 19%), IGHV unmutated (71%, 
64%), and complex karyotype (25%, 21%).
The median time from diagnosis to initiation of ibrutinib 
was 35 months for patients ≥65 YO and 25 months for those 
<65 YO. Eleven percent of older patients were initiated on 
a lower than standard dose of ibrutinib (420 mg daily) in 
contrast to 2% of younger patients (p=0.02). In older patients, 
20% required dose reduction compared to 13% of younger 
patients (p=0.07). Dose interruptions occurred in 46% of older 
and 36% of younger patients (p=0.04); the median duration of 
dose interruption was 13 and 10 days, respectively (p=0.49). 
Ibrutinib discontinuation occurred in similar frequency for 
older and younger patients (25%, 22%). Intolerance was the 
most common reason for discontinuation in both age groups 
(n= 36 and 20, respectively), followed by CLL progression (n= 
6, 6), and Richter’s transformation (n= 5, 4).
Investigator assessed overall and complete response rates 
for ibrutinib were 79% and 15% in patients ≥65 YO and 85% 
and 20% in those <65 YO. There was no difference in PFS 
based on age (HR 1.13, p =0.69), Figure 1. At a median follow 
up of 13.8 months (range 1–76 months), a total of 26 deaths 
were observed. There was a higher proportion of deaths in the 
older cohort (8.7% vs 3.8%, 20 deaths vs 6 deaths), though 
difference in OS did not reach statistical significance (HR 2.1, 
p=0.097). Figure 1. The number of early deaths, defined as 
occurring within the first 12 months of therapy, was 13 in 
patients ≥65 YO compared to 4 in patients <65 YO, p=0.3.
Conclusion
In this cohort of nearly 400 patients who received single 
agent ibrutinib for the front-line treatment of CLL, age did 
Table 1 Patient Characteristics







del 17p (n=158) (n=211)
Absent 70% 71%
Present 30% 29%
TP53 mutation (n=102) (n=117)
Absent 81% 79%
Present 19% 21%
del 11q (n=158) (n=209)
Absent 79% 86%
Present 21% 14%






Ujjani et al                                                                                                                                                            Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                  
Blood and Lymphatic Cancer: Targets and Therapy 2020:10 2
not correlate with response rates, progression-free survi-
val, or overall survival. Nevertheless, a greater than two- 
fold increase in death was noted in patients ≥65-years-old 
compared to the younger cohort. Similar to the data 
reported in the Alliance A041202 study, where the major-
ity of unexplained deaths with ibrutinib occurred within 
the first two years of treatment, early deaths in our analysis 
appeared to occur more frequently in the older patient 
population.1 These data support our initial hypothesis 
that ibrutinib may be associated with a greater early mor-
tality in an older CLL population.
In this analysis, nearly 50% of the older population 
required dose interruptions and 20% required dose reduc-
tions suggesting issues with drug tolerability related to 
AEs. Furthermore, it appears that practitioners anticipated 
an increase in AEs in the older population as they more 
frequently prescribed lower than standard doses of ibruti-
nib at initiation of therapy. Alternatively, this may repre-
sent decreased experience with the drug in the early days 
of approval. Despite these findings, the incidence of 
ibrutinib discontinuation was relatively comparable 
between the different age groups. Additionally, intolerance 
to ibrutinib remained the most common reason for discon-
tinuation of therapy in all patients.
When comparing the grade 3–5 adverse events that 
occurred with ibrutinib in the older Alliance A041202 
and younger ECOG E1912 populations, the most notable 
differences are the increased rates of cardiovascular toxi-
city, specifically atrial fibrillation (9% vs 3%) and hyper-
tension (29% vs 7%).1,2 A recent retrospective analysis of 
562 patients receiving ibrutinib at the Ohio State 
University also noted a marked incidence of new hyper-
tension of 72%.7 Major cardiac events were noted in 17% 
of patients and occurred more frequently in those with new 
or worsening hypertension (19%). In a separate aggregated 
data set of over 1000 patients receiving ibrutinib, 10 
events of sudden death or cardiac arrest were identified.8 
The HELIOS study of BR with or without ibrutinib was 
included in this analysis; 7 events of ≥ grade 3 ventricular 
arrhythmia, cardiac arrests, and sudden deaths were found 
in the ibrutinib-containing arm compared to 0 with BR 
alone.9 The higher incidence of these toxicities raises 
suspicion for a cardiac event as a potential etiology for 
the unexplained, early deaths noted in both Alliance 
A041202 and this analysis; however, investigators were 
unable to confirm this impression. It is also noted that 
early death is not necessarily the same as sudden death. 
Unfortunately, a critical limitation of our analysis is that 
the individual causes of death were not captured uniformly 
as part of this retrospective data review, nor were the past 
cardiac histories. We were unable to identify which, if any, 
adverse events occurred in patients who experienced an 
early death or assign attribution to drug. However, given 
the marked efficacy of ibrutinib and the ability of patients 
to be effectively salvaged after progression, one may 
assume that toxicity may be a key contributing factor.
Given the quickly evolving treatment landscape for 
CLL, one of the more complicated decisions oncologists 
will face is determining the most appropriate novel ther-
apeutic for their individual patient. Ibrutinib is certainly 
a highly effective therapy for patients of all ages, ensuring 
a lengthy PFS and OS in elderly patients with high-risk 
disease. However, as the majority of patients with CLL are 
elderly and many have comorbidities, ensuring tolerability 
is crucial. While our data are hypothesis generating only, 
these findings in combination with those of Woyach et al 
suggest close monitoring of elderly patients treated with 
ibrutinib is warranted for toxicity, particularly in the first 
Figure 1 Survival by age.
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12 months of therapy.1 In addition, patients should be 
educated regarding the potential complications related to 
treatment and symptoms of concern to report.
Fortunately, a number of effective agents have or will 
become available to patients in the near future. The 
CLL-14 study of venetoclax and obinutuzumab recently 
secured the B-cell lymphoma (BCL)-2 inhibitor a role in 
the front-line setting.10 The safety of venetoclax in an 
elderly population with comorbidities, including decreased 
renal function, was demonstrated in this study. However, 5 
fatal adverse events were noted during treatment, primarily 
due to infection, as well as 4 fatal infection events which 
occurred after completion of venetoclax. The incidence of 
severe neutropenia was 53% in this study, highlighting the 
importance in supporting and monitoring patients appro-
priately both during and after therapy. Additionally, there 
are second-generation Bruton tyrosine kinase (BTK) inhi-
bitors in development, including acalabrutinib and zanu-
brutinib, which may be associated with less atrial 
fibrillation.11,12 Their relative risk of early deaths will be 
forthcoming with the results of Phase III trials. The com-
bination of a BTK inhibitor and a BCL-2 inhibitor has also 
demonstrated remarkable efficacy with a shorter required 
treatment duration and thus less time for drug exposure.13 
Whether fixed duration combination strategies will result 
in less toxicity or early deaths is unknown. Moving for-
ward, although the correlation between age and survival 
was not shown to be statistically significant, we do feel 
a greater effort must be focused on understanding whether 
the cause of early mortality in older patients receiving 
ibrutinib is related to the drug or the patient; additionally, 
how best to mitigate this problem which may limit the use 
of this highly effective agent.
Acknowledgments
This abstract of this paper was presented at the 2019 
International Workshop in CLL as a poster presentation 
with interim findings. https://www.iwcll2019.org/wp- 
content/uploads/2019/09/iwCLL-Abstract-Titles.pdf
Author Contributions
All authors made a significant contribution to the work 
reported, whether that is in the conception, study design, 
execution, acquisition of data, analysis and interpretation, 
or in all these areas; took part in drafting, revising or 
critically reviewing the article; gave final approval of the 
version to be published; have agreed on the journal to 
which the article has been submitted; and agree to be 
accountable for all aspects of the work.
Funding
There was no funding for this project.
Disclosure
Chaitra Ujjani reports non-financial supports from 
Pharmacyclics, Abbvie, Genentech, AstraZeneca, and 
Verastem. Anthony Mato reports grants and personal fees 
from TG Therapeutics, Celgene, Abbvie, Loxo, Sunesis, 
Genentech, DTRM, AstraZeneca, Octopharma, Janssen, 
Regeneron, Adaptive, and Pharmacyclics. Brian T Hill reports 
grants, personal fees from Pharmacyclics, Abbvie, 
AstraZeneca. John N Allan reports personal fees from 
Abbvie, Janssen, Pharmacyclics, Genentech, TG 
Therapeutics, Verastem, Sunesis, and Ascentage Pharma 
Group. Frederick Lansigan reports consulting fees from 
Acrotech and is part of the steering committee for Celgene. 
Alan Skarbnik is a consultant for Janssen, Pharmacyclics, 
Abbvie, Celgene, Kite, Alexion, Jazz Pharmaceuticals, and 
AstraZeneca and received payments for lectures including 
service on speakers bureaus from Janssen, Pharmacyclics, 
Abbvie, Celgene, Kite, Alexion, Jazz Pharmaceuticals, 
AstraZeneca, Beigene, Seattle Genetics, Genentech, and 
Verastem. Ryan Jacobs reports grants and/or personal fees 
from Pharmacyclics, Genentech, Abbvie, Verastem, TG 
Therapeutics, Janssen, Astra Zeneca. John Pagel reports per-
sonal fees from Gilead, Beigene, Loxo, and AstraZeneca. 
Danielle Brander reports grants, non-financial support from 
AbbVie, ArQule, Ascentage, Astra Zeneca, BeiGene, DTRM, 
Genentech, Juno/Celgene/BMS, MEI Pharma, Pharmacyclics, 
Pfizer, Teva, TG Therapeutics, Tolero, Verastem, and member-
ships with other guidelines/registry memberships (when spon-
sored or consultant also included under sponsor mentioned): 
NCCN panel member, informCLL registry steering committee 
(AbbVie), REAL registry steering committee (Verastem), and 
Biosimilars outcomes research panel (Pfizer). Bruce Cheson 
reports personal fees from Abbvie, Pharmacyclics, Celgene, 
TG Therapeutics, Beigene, AstraZeneca, and Genentech. Paul 
Barr is consultant for Abbvie, Pharmacyclics, Gilead, 
Genentech, TG therapeutics, Seattle Genetics, Celgene, 
Morphosys, Verastem, AstraZeneca, and Janssen. Lindsey 
Roeker reports family member with minority ownership inter-
est in AbbVie and Abbott Laboratories. Andre Goy reports 
personal fees from Janssen, Pharmacyclics, during the conduct 
of the study; as principal investigator for and received funding 
Ujjani et al                                                                                                                                                            Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                  
Blood and Lymphatic Cancer: Targets and Therapy 2020:10 4
for institution from Genentech-Hoffman La Roche, including 
personal fees from Acerta, AstraZeneca, Celgene, 
Constellation, Infinity, Infinity Verastem, Karyopharm, Kite 
pharma, Elsevier’s PracticeUpdate Oncology, Gilead, 
Medscape, MJH Associates, OncLive Peer Exchange, 
Physcians Education Resource, LLC, Xcenda, and COTA, 
outside the submitted work. Stephen J Schuster reports perso-
nal fees and/or grants from AstraZeneca, Merck, Novartis, 
Juno/Celgene, Genentech/Roche, Loxo Oncology, Tessa 
Therapeutics, AlloGene, BeiGene, and Celgene. Dr Nicole 
Lamanna received research support to institution and advisory 
board honorarium from Abbvie, Astra Zeneca, Beigene, 
Genentech, Gilead, Juno, Janssen, Mingsight, Pharmacyclics, 
TG Therapeutics, Celgene, and Oncternal. Constantine Tam 
reports personal fees from Abbvie, Janssen, Pharmacyclics. 
Mazyar Shadman reports personal fees from Abbvie, 
Genentech, Astra Zeneca, Sound Biologics, Pharmacyclics, 
Verastem, ADC therapeutics, Beigene, Cellectar, BMS, 
Mophosys and Atara Biotherapeutics, grants from Mustang 
Bio, Celgene, Pharmacyclics, Gilead, Genentech, Abbvie, TG 
therapeutics, Beigene, Astra Zeneca, Sunesis, and Beigene. 
The authors report no other conflicts of interest in this work.
References
1. Woyach JA, Ruppert AS, Heerema N, et al. Ibrutinib regimens versus 
chemoimmunotherapy in older patients with untreated CLL. N Engl 
J Med. 2018;379(26):2517–2528. doi:10.1056/NEJMoa1812836
2. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or che-
moimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 
2019;381(5):432–443. doi:10.1056/NEJMoa1817073
3. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia: a report from the 
international workshop on chronic lymphocytic leukemia updating 
the National Cancer Institute-working group 1996 guidelines. Blood. 
2008;111(12):5446–5456. doi:10.1182/blood-2007-06-093906
4. Kaplan EL, Meier P. Nonparametric estimation from incomplete 
observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/ 
01621459.1958.10501452
5. Anderson P, Gill R. Cox’s regression model for counting processes: 
a large sample study. Ann Statist. 1982;10(4):1100–1120. doi:10. 
1214/aos/1176345976
6. Cox DR. Analysis of Survival Data. Routledge; 2018.
7. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident 
cardiovascular events following ibrutinib initiation. Blood. 2019;134 
(22):1919–1928. doi:10.1182/blood.2019000840
8. Lampson B, Yu L, Glynn R, et al. Ventricular arrhythmias and sudden 
death in patients taking ibrutinib. Blood. 2017;129(18):2581–2584. 
doi:10.1182/blood-2016-10-742437
9. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined 
with bendamustine and rituximab compared with placebo, bendamus-
tine, and rituximab for previously treated chronic lymphocytic leu-
kaemia or small lymphocytic lymphoma (HELIOS): a randomised, 
double-blind, Phase 3 study. Lancet Oncol. 2016;17(2):200–211. 
doi:10.1016/S1470-2045(15)00465-9
10. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab 
in patients with CLL and coexisting conditions. N Engl J Med. 
2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281
11. Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in 
patients with chronic lymphocytic leukemia who are intolerant to 
ibrutinib. Blood Adv. 2019;3(9):1553–1562. doi:10.1182/bloodadvances. 
2018030007
12. Tam C, Trotman J, Opat S, et al. Phase 1 study of the selective BTK 
inhibitor zanubrutinib in B-cell malignancies and safety and efficacy 
evaluation in CLL. Blood. 2019;134(11):851–859. doi:10.1182/ 
blood.2019001160
13. Wierda W, Siddiqi T, Flinn I, et al. Phase 2 CAPTIVATE results of 
ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia. 
J Clin Oncol. 2018;36(15_suppl):Abstract 7502. doi:10.1200/ 
JCO.2018.36.15_suppl.7502
Blood and Lymphatic Cancer: Targets and Therapy                                                                           Dovepress 
Publish your work in this journal 
Blood and Lymphatic Cancer: Targets and Therapy is an interna-
tional, peer-reviewed, open access journal focusing on blood and 
lymphatic cancer research, identification of therapeutic targets and 
the optimal use of preventative and integrated treatment interven-
tions to achieve improved outcomes, enhanced survival and quality 
of life for the cancer patient. The manuscript management system is 
completely online and includes a very quick and fair peer-review 
system. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.   
Submit your manuscript here: http://www.dovepress.com/blood-and-lymphatic-cancer-targets-and-therapy-journal
Dovepress                                                                                                                                                            Ujjani et al
Blood and Lymphatic Cancer: Targets and Therapy 2020:10                                                           submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                            
5
